Loading...
•
Jun 30, 2021
Dyne Therapeutics Q2 2021 Earnings Report
Dyne Therapeutics reported financial results for the second quarter of 2021 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $30.0 million, or $0.58 per common share, for the second quarter of 2021. As of June 30, 2021, cash, cash equivalents and marketable securities were $435.6 million.
Preclinical data from DM1 and FSHD programs were presented at scientific meetings.
On track to submit INDs for DM1, DMD and FSHD programs between Q4 2021 and Q4 2022.
Oxana Beskrovnaya, Ph.D., was appointed chief scientific officer in June 2021.
New in vivo data from DM1 and DMD programs to be presented at scientific meetings this fall.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates that subsequent events and developments will cause its views to change and specifically disclaims any obligation to update forward-looking statements.